The Physical Effects of Crohn’s Disease: An Ayurvedic Perspective
Table of Contents
Crohn’s disease is a chronic inflammatory condition of the digestive tract categorized under Inflammatory Bowel Disease (IBD). While Crohn’s primarily affects the gastrointestinal (GI) tract, it has extensive physical effects that can impact other areas of the body, influencing energy, skin, and joint health, among others. Ayurveda views Crohn’s disease as a disorder rooted in imbalances within the body’s doshas—primarily Pitta and Vata—which disrupt digestion, absorption, and immunity (Frawley, 2000).
At EliteAyurveda, our approach to Crohn’s disease emphasizes addressing these doshic imbalances through a holistic framework that aims to restore balance, support digestion, and improve overall health. With personalized, side-effect-free Ayurvedic herbal medications, along with diet and lifestyle guidance, we strive to provide patients with natural, sustainable relief and a better quality of life (Lad, 2002).
Understanding Crohn’s Disease in Ayurveda
In Ayurveda, Crohn’s disease is seen as a result of aggravated Pitta and Vata doshas. Pitta, associated with heat and transformation, governs metabolic functions, while Vata, associated with movement, influences absorption and elimination. When these doshas are out of balance, digestive fire (Agni) weakens, resulting in toxin (Ama) accumulation and chronic inflammation (Sharma & Clark, 2011).
- Pitta Aggravation: Excessive Pitta causes inflammation and heat, leading to symptoms such as abdominal pain, diarrhea, and ulceration in the digestive tract.
- Vata Aggravation: Vata’s dry, irregular qualities contribute to erratic digestion, discomfort, and compromised absorption.
- Ama (Toxins): Ama, or accumulated toxins, results from impaired digestion and further contributes to inflammation and immune dysfunction, key factors in Crohn’s disease.
The Physical Effects of Crohn’s Disease
Crohn’s disease manifests in the body through a variety of physical symptoms, each corresponding to specific doshic imbalances. EliteAyurveda’s goal is to alleviate these physical effects through a personalized approach that targets the root imbalances, aiming to reduce discomfort and improve long-term health (Tiwari, 2001).
1. Digestive Disturbances and Abdominal Pain
Digestive disturbances are common in Crohn’s disease, with symptoms like persistent diarrhea, abdominal cramping, and bloating. These are often due to inflammation and ulceration in the intestines.
- Ayurvedic Insight: Ayurveda views these symptoms as signs of Pitta and Vata imbalances. Cooling and grounding measures, alongside personalized herbal support, help reduce inflammation, soothe the digestive tract, and support regular bowel movements.
2. Nutrient Malabsorption and Weight Loss
Inflammation and damage to the intestinal lining can interfere with nutrient absorption, leading to deficiencies in essential vitamins and minerals. This often results in weight loss and fatigue.
- Ayurvedic Insight: Poor digestion (weakened Agni) and Ama hinder nutrient absorption, affecting energy levels and overall health. By strengthening Agni through balanced diets and herbal medications, EliteAyurveda works to improve nutrient uptake and restore energy levels naturally.
3. Chronic Fatigue and Low Energy
Chronic inflammation and nutrient deficiencies contribute to ongoing fatigue and low energy levels, which are common among individuals with Crohn’s disease.
- Ayurvedic Insight: Fatigue is associated with Vata imbalance and depleted Agni, impacting the body’s ability to generate and sustain energy. EliteAyurveda addresses this through personalized, side-effect-free herbal medications and grounding lifestyle practices, helping patients restore vitality.
4. Joint Pain and Inflammation
Joint pain and inflammation, sometimes referred to as enteropathic arthritis, are common complications associated with Crohn’s disease and stem from systemic inflammation.
- Ayurvedic Insight: Joint pain relates to Vata and Pitta aggravation, which create dryness and heat in the joints. Our approach focuses on reducing inflammation and providing personalized Ayurvedic herbal support for joint health, helping patients manage pain and maintain mobility.
5. Skin Problems and Oral Lesions
Crohn’s disease may also lead to skin issues like rashes, inflammation, and oral lesions due to nutrient deficiencies and systemic inflammation.
- Ayurvedic Insight: In Ayurveda, skin and oral health are reflections of Pitta and digestive health. Calming Pitta and supporting digestive balance through lifestyle changes and side-effect-free herbs can alleviate these symptoms, promoting clear, healthy skin.
6. Bone Density Loss
Crohn’s disease may lead to decreased bone density and osteoporosis, often due to malabsorption and chronic inflammation.
- Ayurvedic Insight: Bone health (Asthi dhatu) relies on strong digestion (Agni) and nutrient absorption. EliteAyurveda emphasizes personalized dietary support and lifestyle practices that maintain mineral balance and strengthen bone integrity over time.
EliteAyurveda’s Holistic Approach to Managing Crohn’s Disease
At EliteAyurveda, we believe in a comprehensive approach to Crohn’s disease that goes beyond symptom management to address the root causes. Our strategy includes personalized, side-effect-free Ayurvedic herbal medications, dietary adjustments, lifestyle modifications, and stress reduction techniques tailored to each patient’s needs.
1. Balancing Diet for Digestive Health and Immune Stability
A balanced diet that aligns with individual doshic needs is essential for managing Crohn’s disease effectively. At EliteAyurveda, we emphasize foods that soothe Pitta, stabilize Vata, and support healthy digestion.
- Agni-Supportive Foods: We recommend easy-to-digest foods that strengthen Agni without overwhelming the digestive system. Personalized meal plans ensure gentle nourishment that meets the unique requirements of Crohn’s patients.
- Avoiding Aggravating Foods: Foods that aggravate Pitta or are hard to digest, like spicy or processed items, are minimized to reduce inflammation.
2. Personalized, Side-Effect-Free Ayurvedic Herbal Medications
Herbal medications in Ayurveda are tailored to support the body’s unique constitution and balance doshas gently. EliteAyurveda’s personalized, side-effect-free herbal medications aim to:
- Reduce Inflammation: Cooling herbs help calm Pitta-driven inflammation, soothing the gut lining.
- Improve Digestion and Absorption: Herbs that support Agni improve nutrient absorption and energy levels.
- Strengthen Immune Health: Our herbs work to balance immune response and reduce overactivity, minimizing the triggers for flare-ups.
3. Establishing a Routine (Dinacharya) for Stability and Resilience
Ayurveda recommends a structured daily routine (Dinacharya) to stabilize Vata and Pitta, reducing the likelihood of flare-ups and supporting long-term health.
- Consistent Mealtimes and Rest: Eating and sleeping on a regular schedule supports healthy digestion and reduces stress, two crucial factors in managing Crohn’s disease.
- Gentle Movement and Breathwork: Yoga and Pranayama help improve circulation and oxygenation, promoting overall resilience and reducing inflammation.
4. Stress Management for Holistic Health
Crohn’s disease can be both physically and emotionally challenging. EliteAyurveda emphasizes mind-body balance, helping patients manage stress and improve their overall well-being.
- Mindfulness and Meditation: Techniques like meditation help calm the mind, reduce stress, and prevent Pitta and Vata imbalances that can aggravate symptoms.
- Holistic Emotional Support: We provide resources that empower patients to manage the emotional impact of Crohn’s, improving resilience and quality of life.
Long-Term Benefits of Ayurvedic Management for Crohn’s Disease
The Ayurvedic approach to Crohn’s disease focuses on building long-term health by addressing the root causes of inflammation, digestive imbalance, and immune dysfunction.
- Reduced Flare-Ups and Improved Digestion: By strengthening Agni and balancing Pitta and Vata, Ayurveda helps manage symptoms, reduce flare-up frequency, and improve digestion.
- Enhanced Immune Stability: Our immune-supportive practices promote a balanced immune response, reducing reactivity and the cycle of inflammation associated with Crohn’s disease.
- Better Quality of Life and Overall Health: Holistic care improves physical resilience, boosts energy levels, and reduces discomfort, leading to a higher quality of life for patients.
Why Choose EliteAyurveda for Crohn’s Disease Management?
At EliteAyurveda, we provide individualized care for managing Crohn’s disease with a comprehensive Ayurvedic approach. By addressing both the symptoms and root causes, our personalized treatments—including side-effect-free herbal medications, dietary guidance, lifestyle adjustments, and immune-supportive practices—help patients achieve natural, sustainable relief and enhanced well-being. Our experienced practitioners work closely with each patient to understand their unique constitution, challenges, and goals, guiding them toward balanced, resilient health.
If you’re seeking a holistic approach to Crohn’s disease that emphasizes natural, long-term solutions, EliteAyurveda offers compassionate care grounded in Ayurvedic wisdom to help you live more comfortably and healthfully.
Related-
Know more about ayurveda treatments for Crohn’s Disease
GET IN TOUCH
Schedule a Visit
References
References
1.
Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010 Feb;105(2):289-97. [PubMed]2.
Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010 Oct;139(4):1147-55. [PMC free article] [PubMed]3.
Lightner AL, McKenna NP, Alsughayer A, Loftus EV, Raffals LE, Faubion WA, Moir C. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn’s patients. J Pediatr Surg. 2019 Oct;54(10):2162-2165. [PubMed]4.
Marazuela García P, López-Frías López-Jurado A, Vicente Bártulos A. Acute abdominal pain in patients with Crohn’s disease: what urgent imaging tests should be done? Radiologia (Engl Ed). 2019 Jul-Aug;61(4):333-336. [PubMed]5.
Aksan A, Farrag K, Stein J. An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):95-97. [PubMed]6.
Hwang JH, Yu CS. Depression and resilience in ulcerative colitis and Crohn’s disease patients with ostomy. Int Wound J. 2019 Mar;16 Suppl 1(Suppl 1):62-70. [PMC free article] [PubMed]7.
Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review. J Clin Pharm Ther. 2019 Aug;44(4):495-507. [PubMed]8.
Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedian S, Cheon JH, Cho J, Dayani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JY, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK, International Multiple Sclerosis Genetics Consortium. International IBD Genetics Consortium. Barrett JC, Alizadeh BZ, Parkes M, Bk T, Daly MJ, Kubo M, Anderson CA, Weersma RK. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015 Sep;47(9):979-986. [PMC free article] [PubMed]9.
Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D’Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D’Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010 Dec;42(12):1118-25. [PMC free article] [PubMed]10.
Lee HS, Oh H, Yang SK, Baek J, Jung S, Hong M, Kim KM, Shin HD, Kim KJ, Park SH, Ye BD, Han B, Song K. X Chromosome-wide Association Study Identifies a Susceptibility Locus for Inflammatory Bowel Disease in Koreans. J Crohns Colitis. 2017 Jul 01;11(7):820-830. [PubMed]11.
Zaidi D, Wine E. Regulation of Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κβ) in Inflammatory Bowel Diseases. Front Pediatr. 2018;6:317. [PMC free article] [PubMed]12.
Ghersin I, Khteeb N, Katz LH, Daher S, Shamir R, Assa A. Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study. Aliment Pharmacol Ther. 2019 Mar;49(5):556-563. [PubMed]13.
Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A, Carroll MW, Hazlewood G, Jacobson K, Jelinski S, Deardon R, Jones JL, Kuenzig ME, Leddin D, McBrien KA, Murthy SK, Nguyen GC, Otley AR, Panaccione R, Rezaie A, Rosenfeld G, Peña-Sánchez JN, Singh H, Targownik LE, Kaplan GG. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology. 2019 Apr;156(5):1345-1353.e4. [PubMed]14.
Gálvez J. Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN Inflamm. 2014;2014:928461. [PMC free article] [PubMed]15.
Targan SR. Biology of inflammation in Crohn’s disease: mechanisms of action of anti-TNF-a therapy. Can J Gastroenterol. 2000 Sep;14 Suppl C:13C-16C. [PubMed]16.
Kanai T, Watanabe M, Okazawa A, Nakamaru K, Okamoto M, Naganuma M, Ishii H, Ikeda M, Kurimoto M, Hibi T. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn’s disease. Gastroenterology. 2000 Dec;119(6):1514-23. [PubMed]17.
Greuter T, Piller A, Fournier N, Safroneeva E, Straumann A, Biedermann L, Godat S, Nydegger A, Scharl M, Rogler G, Vavricka SR, Schoepfer AM., Swiss IBD Cohort Study Group. Upper Gastrointestinal Tract Involvement in Crohn’s Disease: Frequency, Risk Factors, and Disease Course. J Crohns Colitis. 2018 Nov 28;12(12):1399-1409. [PubMed]18.
Fumery M, Pariente B, Sarter H, Savoye G, Spyckerelle C, Djeddi D, Mouterde O, Bouguen G, Ley D, Peneau A, Dupas JL, Turck D, Gower-Rousseau C., Epimad Group. Long-term outcome of pediatric-onset Crohn’s disease: A population-based cohort study. Dig Liver Dis. 2019 Apr;51(4):496-502. [PubMed]19.
Owczarek D, Cibor D, Głowacki MK, Rodacki T, Mach T. Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. World J Gastroenterol. 2014 Jan 07;20(1):53-63. [PMC free article] [PubMed]20.
Fadeeva NA, Korneeva IA, Knyazev OV, Parfenov AI. Biomarkers of inflammatory bowel disease activity. Ter Arkh. 2018 Dec 30;90(12):107-111. [PubMed]21.
Parfenov AI, Knyazev OV, Kagramanova AV, Fadeeva NA. Personalized medicine in the treatment of inflammatory bowel diseases. Ter Arkh. 2018 Feb 15;90(2):4-11. [PubMed]22.
Kedia S, Das P, Madhusudhan KS, Dattagupta S, Sharma R, Sahni P, Makharia G, Ahuja V. Differentiating Crohn’s disease from intestinal tuberculosis. World J Gastroenterol. 2019 Jan 28;25(4):418-432. [PMC free article] [PubMed]23.
Moon JS. Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases. Pediatr Gastroenterol Hepatol Nutr. 2019 Jan;22(1):50-56. [PMC free article] [PubMed]24.
Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018 Apr;113(4):481-517. [PubMed]25.
Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020 Jan 01;14(1):4-22. [PubMed]26.
Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF., European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014 Jun;8(6):443-68. [PubMed]